Abstract
A multicentre, double-blind, treat-to-target trial evaluated the efficacy of faster-acting insulin aspart (faster aspart) vs. insulin aspart (IAsp) in adults with uncontrolled type 2 diabetes (T2D) on basal insulin and oral antidiabetic drugs. After optimizing basal insulin glargine during an 8-week run-in (mean HbA1c at baseline 7.9%), subjects were randomized 1:1 to mealtime faster aspart (n=345) or IAsp (n=344), each with insulin glargine and metformin. Bolus insulin was titrated using a simple, daily, patient-driven titration algorithm.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
